EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Radiofrequency balloon ablation: 1-year outcomes of the AURORA study

Ilaria My, Boris Schmidt, Laura Rottner, Shota Tohoku, Marc Lemoine, David Schaack, Fabian Moser, Lukas Urbanek, Julius Obergassel, Djemail Ismaili, Jun Hirokami, Paulus Kirchhof und 7 weitere

Journal of Interventional Cardiac Electrophysiology · 2024

DOI: 10.1007/s10840-024-01938-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Interventional Cardiac Electrophysiology, 2024. Verfasst von Ilaria My und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, …. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A novel irrigated radiofrequency balloon (RFB) for pulmonary vein isolation (PVI) integrated into a 3D mapping platform was recently launched.

Methods

Patients undergoing a first atrial fibrillation (AF) ablation at two German high-volume EP centers were included into the prospective AURORA registry. All patients underwent clinical follow-up (FU) at 90, 180, and 360 days following ablation including 48-h Holter ECGs.

Results

A total of 99 patients were enrolled (43/99 (43.4%) women, median age 67 years (interquartile range [IQR] 59–74), 43/99 (43.4%) persistent AF (Pers-AF), median left ventricular ejection fraction (LVEF) 60% (IQR 62–55)). Eighty-eight patients completed the follow-up. Acute PVI was achieved in 383/383 (100%) PV. Single-shot PVI was achieved in 211/383 (55.1%) PVs. Primary adverse events occurred in 3% of patients (1 postprocedural pharyngeal bleeding, 1 myocardial infarction, 1 non-cardiovascular death); no pericardial effusion, stroke, or phrenic nerve paralysis was observed. Median ablation and procedure times were 23 (IQR 18–32) and 67 (IQR 57–85) min, respectively. Median dose area product was 761 (IQR 509–1534) mGycm 2 . AF-free survival after a median FU of 361 (IQR 261–375) days was 78.4% for paroxysmal AF (PAF) and 75.4% for Pers-AF ( p value = 0.828). Early recurrence of atrial tachyarrhythmia at the 90-day visit was the only independent predictor for AF recurrence at 1 year upon multiple regression analysis (hazard ratio [HR] 3.198; 95% confidence interval [95% CI] 1.036–10.32, p value = 0.0433).

Conclusion

RFB-based PVI is acutely successful, appears safe, and has comparable rhythm outcomes to other single-shot AF ablation tools. A recurrence of AF at 90 days predicts later AF recurrence. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationPulmonary VeinsHumansFemaleMaleAgedMiddle AgedProspective StudiesTreatment OutcomeGermanyRegistriesFollow-Up StudiesElectrocardiography, AmbulatoryRecurrence

Stichwörter der Autor:innen

Atrial fibrillationPulmonary vein isolationRadiofrequency balloonSingle-shot isolationThermal energy

Autor:innen und Institutionen

  • Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. ilariamy@libero.it.
  • Cardioangiologisches Centrum Bethanien, Frankfurt am Main, Germany.
  • Universitätsklinikum Frankfurt, Med. Klinik 3, Kardiologie, Frankfurt am Main, Germany.
  • Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.

Förderung

  • Universitätsklinikum Hamburg-Eppendorf (UKE)

Zitieren

APA

My, I., Schmidt, B., Rottner, L., Tohoku, S., Lemoine, M., Schaack, D., Moser, F., Urbanek, L., Obergassel, J., Ismaili, D., Hirokami, J., Kirchhof, P., Plank, K., Reissmann, B., Ouyang, F., Rillig, A., Chun, J., Metzner, A., & Bordignon, S. (2024). Radiofrequency balloon ablation: 1-year outcomes of the AURORA study. Journal of Interventional Cardiac Electrophysiology. https://doi.org/10.1007/s10840-024-01938-0

Vancouver

My I, Schmidt B, Rottner L, Tohoku S, Lemoine M, Schaack D, et al. Radiofrequency balloon ablation: 1-year outcomes of the AURORA study. Journal of Interventional Cardiac Electrophysiology. 2024. doi:10.1007/s10840-024-01938-0

BibTeX
@article{My2024,
  author = {My, Ilaria and Schmidt, Boris and Rottner, Laura and Tohoku, Shota and Lemoine, Marc and Schaack, David and Moser, Fabian and Urbanek, Lukas and Obergassel, Julius and Ismaili, Djemail and Hirokami, Jun and Kirchhof, Paulus and Plank, Karin and Reissmann, Bruno and Ouyang, Feifan and Rillig, Andreas and Chun, Julian and Metzner, Andreas and Bordignon, Stefano},
  title = {Radiofrequency balloon ablation: 1-year outcomes of the AURORA study},
  journal = {Journal of Interventional Cardiac Electrophysiology},
  year = {2024},
  doi = {10.1007/s10840-024-01938-0}
}
Kostenlos starten →